<DOC>
	<DOCNO>NCT01860664</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness hydrocortisone ophthalmic ointment compare placebo treatment Allergic Conjunctivitis .</brief_summary>
	<brief_title>Hydrocortisone Ophthalmic Ointment 0.5 % Treatment Allergic Conjunctivitis</brief_title>
	<detailed_description>Compare safety efficacy Hydrocortisone Ophthalmic Ointment 0.5 % v . Placebo reduction sign symptom associate allergic conjunctivitis . Demonstration efficacy statistically significant improvement itch 0 4 patient subjective assessment itch score compare vehicle arm least 25 % ( 1 full unit ) improvement itch score . Efficacy bulbar redness score would indicate statistically significant improvement redness zero 4 base investigator objective assessment compare vehicle group . Differences least 25 % four point scale would consider clinically significant attain majority time point .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Inclusion Criteria ) Diagnosis allergic conjunctivitis . b ) Must least 18 year age c ) Must able willing comply treatment follow procedure ) Best correct visual acuity 0.3 logMAR well ( Snellen equivalent score 20/40 good ) eye Visit 1 e ) Conjunctival redness score â‰¥1.5 least one eye Visit 1 f ) Subject report itching assessment &gt; 2.0 least 1 eye Visit 1 g ) Mean IOP &gt; 8 &lt; 24 eye h ) If female childbearing potential , nonlactating nonpregnant , must willing use approve birth control method duration study , must negative urine pregnancy test . ( Urine pregnancy test conduct Visit 1 subject completes Informed Consent Document prior study procedure perform . ) 5.4 Exclusion Criteria 1 . Unwilling unable discontinue use contact lens study 2 . Uncontrolled medical condition may judgment investigator confound study assessment limit compliance . 3 . Known sensitivity corticosteroid know `` steroid responder '' 4 . Known hypersensitivity study drug component contraindication hydrocortisone ophthalmic ointment 5 . Use systemic topical ophthalmic antihistamine agent within 72 hour visit 1 , discontinue study 6 . Participation ophthalmic drug device research study within 30 day prior entry study . 7 . Regular use systemic topical ophthalmic nonsteroidal antiinflammatory agent ( NSAID ) , analgesic 8 . Younger 18 year age , Male Female 9 . Unwilling provide write informed consent 10 . Unlikely complete study visit 11 . Patients diagnose Glaucoma 12 . History ocular condition , opinion investigator , could affect study parameter include , limited , glaucoma , blepharitis , meibomian gland disease , follicular conjunctivitis , and/or active ocular infection inflammation . 13 . Use concurrent therapy allergic conjunctivitis , prescription counter . 14 . Prohibited medication include : 1. topical ophthalmic systemic corticosteroid 2. topical ophthalmic/nasal antihistamine ( 72 hour washout period prior baseline/screening visit use throughout duration study ) 3. artificial tears/ocular lubricant ( 72 hour washout period use throughout duration study ) 4. topical ophthalmic/nasal steroid ( 14 day washout period prior baseline/screening visit use throughout duration study ) ( Washout period begin Informed Consent Document complete subject . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>allergy</keyword>
	<keyword>allergic</keyword>
	<keyword>conjunctivitis</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>hydrocortisone</keyword>
	<keyword>ophthalmic</keyword>
	<keyword>ointment</keyword>
</DOC>